Fate Operating Margin from 2010 to 2026
| FATE Stock | USD 1.19 0.02 1.65% |
Check Fate Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Fate Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 22.9 M, Interest Expense of 7.1 M or Selling General Administrative of 89.6 M, as well as many indicators such as Price To Sales Ratio of 15.03, Dividend Yield of 0.0 or PTB Ratio of 0.5. Fate financial statements analysis is a perfect complement when working with Fate Therapeutics Valuation or Volatility modules.
Fate | Operating Margin | Build AI portfolio with Fate Stock |
Analyzing Fate Therapeutics's Operating Margin over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Operating Margin has evolved provides context for assessing Fate Therapeutics's current valuation and future prospects.
Latest Fate Therapeutics' Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of Fate Therapeutics over the last few years. It is Fate Therapeutics' Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Fate Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (19.95) % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
Fate Operating Margin Regression Statistics
| Arithmetic Mean | (9.88) | |
| Coefficient Of Variation | (47.82) | |
| Mean Deviation | 3.91 | |
| Median | (11.36) | |
| Standard Deviation | 4.73 | |
| Sample Variance | 22.34 | |
| Range | 15.2043 | |
| R-Value | 0.09 | |
| Mean Square Error | 23.65 | |
| R-Squared | 0.01 | |
| Significance | 0.74 | |
| Slope | 0.08 | |
| Total Sum of Squares | 357.42 |
Fate Operating Margin History
About Fate Therapeutics Financial Statements
Fate Therapeutics stakeholders use historical fundamental indicators, such as Fate Therapeutics' Operating Margin, to determine how well the company is positioned to perform in the future. Although Fate Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Fate Therapeutics' assets and liabilities are reflected in the revenues and expenses on Fate Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Fate Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California. Fate Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 542 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| VTI | Vanguard Total Stock | |
| RIOT | Riot Blockchain | |
| TSLA | Tesla Inc |
Check out the analysis of Fate Therapeutics Correlation against competitors. For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Will Biotechnology sector continue expanding? Could Fate diversify its offerings? Factors like these will boost the valuation of Fate Therapeutics. Market participants price Fate higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Fate Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.33) | Revenue Per Share | Quarterly Revenue Growth (0.43) | Return On Assets | Return On Equity |
The market value of Fate Therapeutics is measured differently than its book value, which is the value of Fate that is recorded on the company's balance sheet. Investors also form their own opinion of Fate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fate Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Fate Therapeutics' market value can be influenced by many factors that don't directly affect Fate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Fate Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.